Introduction {#S1}
============

Breast cancer is not one disease, but rather, represents at least six subtypes ([@R25]; [@R33]; [@R11]). These include luminal A, luminal B, normal-like, HER2-enriched, claudin-low and basal-like, each with unique gene expression profiles and distinct clinical outcomes. The majority of breast cancer cases (60-80 percent) comprise the luminal/estrogen receptor-α positive (ER+) tumors, while basal-like breast carcinoma accounts for 10-15 percent of all cases. The basal-like subtype, often clinically observed as "triple-negative" tumors (negative for ERα, PR, and HER2), is of particular interest because treatment options are limited to chemotherapy only and patients with this disease typically have poor outcomes. One contribution to the poor outcome of basal-like breast cancer patients may be their high cellular proliferation rates, which is manifested transcriptionally as the high expression of the "proliferation signature"; this is a dominant gene signature that is a marker of cell proliferation rates across multiple tumor types ([@R11]; [@R42]). *B-Myb*, a gene with known cell cycle control functions and implications in tumorigenesis ([@R29]), is one of approximately 100 genes that define the proliferation signature.

B-Myb is a member of the vertebrate MYB family of nuclear transcription factors. In humans this family is comprised of *A-Myb* (MYBL1), *B-Myb* (MYBL2), and *c-Myb* (MYB). Each family member is able to recognize and bind to the same DNA consensus sequence (PyAAC(G/T)G) to promote gene transcription; however, varying tissue-specific expression patterns, as well as protein-protein interactions with unique co-factors, suggests that distinct biological roles exist for each MYB family member ([@R27]; [@R29]). Found in the genomes of both plants and animals, MYB proteins are conserved throughout evolution and control processes from flavonoid production to cellular proliferation ([@R27]; [@R13]). In contrast to vertebrates, invertebrates contain only one MYB protein, which in Drosophila (dMYB) is phylogenetically and functionally complementary to vertebrate B-Myb, suggesting B-Myb to be the most ancient family member ([@R5]). The expression of *B-Myb*, unlike *c-Myb* and *A-Myb* ([@R20]; [@R36]; [@R35]; [@R21]; [@R16]), is ubiquitously expressed in virtually all proliferating cells as a regulator of cell cycle progression and plays an essential role in vertebrate development; knocking out murine *B-Myb* causes early embryonic lethality (E4.5-6.5) resulting from unsuccessful inner cell mass formation ([@R34]).

MYB family members have been implicated in tumorigenesis for several decades. The *c-Myb* proto-oncogene was first identified as the mammalian homolog of *v-myb*, which is the transforming gene transmitted by the avian myeloblastosis and E26 retroviruses causing acute leukemia in birds ([@R14]; [@R15]). *A-* and *B-Myb* were later discovered during low stringency screening of human cDNA libraries ([@R23]). The *B-Myb* chromosomal locus, 20q13, is amplified and/or highly expressed in a variety of tumor types including breast, prostate, liver and ovarian carcinomas, and in most cases this high expression portends a poor prognosis ([@R29]). *B-Myb* is also an important marker of poor outcome in embryonal tumors of the central nervous system (CNS) ([@R26]). Recently, a nonsynonymous *B-Myb* germline variant (rs2070235) causing a serine to glycine amino acid change (S427G) was linked to a decrease in overall cancer risk for neuroblastomas, chronic myelogenous leukemia, and colon cancers in a combined dataset of cases and controls ([@R30]). However, the molecular roles of *B-Myb* in disease progression, as well as its transcriptional target genes in the mammary gland, are still poorly understood. To gain insight into *B-Myb* and its involvement in breast cancer, we analyzed the expression of *B-Myb* across the breast cancer subtypes, examined its relationship to survival and pathological complete response and the correlation of variant rs2070235 to disease risk. We also manipulated the expression of *B-Myb* and the S427G variant in normal and tumor derived mammary cell lines and observed alterations in drug sensitivity and cell cycle profiles.

RESULTS {#S2}
=======

High *B-Myb* Expression in Breast Tumors Predicts Poor Outcome {#S3}
--------------------------------------------------------------

To asses the relevance of *B-Myb* gene expression across the breast cancer subtypes, breast tumor microarray data from the Netherlands Cancer Institute (NKI-295, n=295, ([@R39])) was analyzed. Tumor samples were classified into five breast cancer subtypes using a single sample centroid-based predictor as described ([@R11]). An ANOVA analysis performed on these stratified samples showed that *B-Myb* expression differs significantly across the subtypes and was highest in basal-like tumors ([Figure 1](#F1){ref-type="fig"}).

To test for correlations between *B-Myb* mRNA expression alone and patient outcome, we analyzed the NKI patients not receiving adjuvant systemic treatment (i.e. local treatment only; n=165). This allowed us to better identify the prognostic abilities of *B-Myb* without the confounding data of treatment response. The NKI "local-only" tumors were rank ordered into halves (low/high) based on their *B-Myb* expression levels and analyzed for overall survival (OS) and relapse free survival (RFS) by Kaplan-Meier analysis. Poor OS and RFS were highly correlated (p\<0.001) with *B-Myb* high expression levels in these NKI samples ([Figure 2A](#F2){ref-type="fig"}, and RFS data not shown). *B-Myb* expression alone was also able to significantly predict OS on local-only treated luminal A subtype tumors (n=72) ([Figure 2B](#F2){ref-type="fig"}), luminal B (n=26) ([Figure 2C](#F2){ref-type="fig"}), HER2+/ER− (n=21) ([Figure 2D](#F2){ref-type="fig"}), but not basal-like tumors (n=30) ([Supplementary Figure 1A](#SD1){ref-type="supplementary-material"}). We then evaluated the prognostic ability of *B-Myb* using two other published breast tumor microarray datasets ([@R17]; [@R41]). [@R41] (n=286) consisted of microarrays on untreated, lymph-node-negative primary ER+ and ER-breast cancers with relapse data, and *B-Myb* was capable of predicting RFS in these patients ([Figure 2E](#F2){ref-type="fig"}). On this same dataset, *B-Myb* also predicted RFS in the ER+ patient subset (n=209), but not the ER− subset (n=77) ([Supplementary Figures 1B, C](#SD1){ref-type="supplementary-material"}). Another dataset consisting of primary invasive tumors ([@R17]) (n=234) was tested and similar results were found ([Figure 2F](#F2){ref-type="fig"}).

To determine if *B-Myb* expression was involved with pathologic complete response (pCR), we used the data of [@R8], where microarrays were performed on pre-treatment breast tumors from patients receiving neoadjuvant paclitaxel, followed by 5FU-Adriamycin-Cyclophosphamide (T/FAC; n=133). Again, samples were split into two groups based on *B-Myb* expression (low/high). *B-Myb* high expression was again associated subtype (data not shown) and with pCR, as calculated by chi-square test (p=0.008; [Supplementary Table 1](#SD1){ref-type="supplementary-material"}).

*B-Myb* Germline Variant (rs2070235) Increases Risk of Basal-Like Breast Cancer {#S4}
-------------------------------------------------------------------------------

A nonsysnonymous germline *B-Myb* variant exists that causes a serine to glycine substitution (rs2070235, S427G). This non-conservative change prompted us to look for correlations between this variant and baseline susceptibility risk in the population-based Carolina Breast Cancer Study/CBCS ([@R22]). Odds ratios for the *B-Myb* genotype and all breast cancer cases, luminal A, and basal-like cases, versus controls are presented in [Table 1](#T1){ref-type="table"}. There was no association between *B-Myb* genotype and all breast cancer (p=0.71); however a statistically significant association was observed for basal-like breast cancer (p=0.047), but not luminal A (p=0.14). No association was observed for *B-Myb* genotype and the other breast cancer subtypes (luminal B, HER2+/ER− and unclassified: data not shown). Odds ratios were similar in African-Americans and Caucasians (likelihood-ratio tests/LRTs for interaction with race were not statistically significant). Among controls in the CBCS, allele frequencies for the *B-Myb* G allele were higher in African-Americans (0.27) than Caucasians (0.08).

Ectopic Expression of *B-Myb* Increases Sensitivity to TOP2A Inhibitors {#S5}
-----------------------------------------------------------------------

Given *B-Myb*'s expression within the proliferation signature, evidence suggesting that rapidly growing tumors may be more chemotherapy sensitive, and the correlation between *B-Myb* expression and pathological complete response, we sought to determine if ectopic expression of *B-Myb in vitro* had an effect on sensitivity to chemotherapeutics. *B-Myb*, and the *B-Myb* S427G variant, were overexpressed in two *hTERT*-immortalized human mammary epithelial cell lines (HME-CC, ME16C) and two basal-like tumor derived lines (SUM102, SUM149) ([Supplementary Figure 2](#SD1){ref-type="supplementary-material"}). Low endogenous B-Myb levels were detectable by western blot in the tumor lines, and in all lines by microarray analysis for mRNA levels ([Supplementary Figure 2](#SD1){ref-type="supplementary-material"} and data not shown). All cell lines were also genotyped for rs2070235 and identified as homozygous for the major allele. It is important to note that the two normal tissue derived cell lines have a basal-like phenotype when assessed by gene expression analysis ([@R37]), thus, these lines represent appropriate counterparts to the two basal-like tumor lines.

Cells ectopically expressing *B-Myb*, or S427G variant, were treated with a panel of chemotherapy agents including two DNA topoisomerase IIα (TOP2A) inhibitors (doxorubicin, etoposide), a DNA topoisomerase I inhibitor (camptothecin), a microtubule stabilizer (paclitaxel), a DNA alkylating agent (carboplatin), and an antimetabolite (5-flurouracil), most of which are commonly used in breast cancer treatment. HME-CC cells overexpressing *B-Myb*, or variant, were approximately twice as sensitive to the two DNA topoisomerase IIα inhibitors, based on IC50 assays, compared to the parental cell lines, but showed no significant change in sensitivity to the other drugs ([Figure 3A](#F3){ref-type="fig"}). To further test *B-Myb* effects on chemotherapy sensitivity, another immortalized HMEC line (ME16C) and two basal-like tumor derived cell lines (SUM102, SUM149) were tested. The ME16C cell line was also sensitized to TOP2A inhibitors by *B-Myb* expression, but not to treatment with other chemotherapeutics ([Figure 3B](#F3){ref-type="fig"} and data not shown); however, this sensitivity profile was not observed in either of the two basal-like tumor derived lines ([Figures 3C and D](#F3){ref-type="fig"}), where *B-Myb* expression had no apparent effect. The *B-Myb* S427G variant was also tested in each cell line for chemosensitivity and behaved similarly to the cells overexpressing wild-type *B-Myb* ([Figure 3A](#F3){ref-type="fig"} and data not shown).

Gene Expression Analysis of Cell Lines Ectopically Expressing *B-Myb* {#S6}
---------------------------------------------------------------------

To look for gene expression changes in cells overexpressing *B-Myb*, and to further assess the chemotherapy phenotype, microarrays were performed on the HME-CC cell lines. Under normal, non-confluent conditions, the only statistically significant expression difference (Significance Analysis of Microarrays/SAM analysis ([@R38]) with a 3% false discovery rate/FDR) was *B-Myb* itself; also, no gene expression differences were observed between the *B-Myb* and *B-Myb* S427G-expressing cell lines. Since a chemotherapy-related phenotype was observed with TOP2A inhibitors, we tested the cell lines after treatment with the 72 hour IC50 dose of doxorubicin. In a two-class SAM analysis (i.e. doxorubicin-treated HME-CC control vs. doxorubicin-treated HME-CC+*B-Myb*), 217 genes were identified (FDR \<3%; [Supplementary Table 2](#SD1){ref-type="supplementary-material"}).

An EASE (Expression Analysis Systematic Explorer) analysis ([@R10]) was performed and many cell cycle related gene ontology categories were identified as being significantly enriched ([Table 2](#T2){ref-type="table"}). Therefore, in doxorubicin treated cells overexpressing *B-Myb* there was significantly higher expression of many cell cycle genes compared to the treated control.

B-Myb is thought to be a transcriptional regulator of G2/M genes ([@R44]). To determine if the 217-gene SAM list was enriched for genes within a particular phase of the cell cycle, each gene was assigned to a specific phase by comparing them to a known list derived from a precise cell cycle microarray time course experiment ([@R43]), or by literature search. Out of 217 significant genes, 101 genes were identified as being specifically induced during the cell cycle and 60/101 genes were assigned as G2/M-specific genes ([Figure 4](#F4){ref-type="fig"}). In addition, previous known B-Myb target genes were present on the SAM list including *CDC2*, *Cyclin B1*, *BIRC5*, and the B-Myb binding partner, *LIN-9*.

Cell Cycle Profiles of *B-Myb* Overexpressing Cells {#S7}
---------------------------------------------------

Since *B-Myb* expressing, doxorubicin treated cells produced a significant G2/M-enriched gene list, we hypothesized that the cell cycle profiles of these cells may be different than treated controls. *B-Myb* expressing HME-CC and empty vector controls were both treated with a range of doxorubicin doses for 48 hours and their cell cycle profiles analyzed for DNA content using flow cytometry. At zero dose or high dose of doxorubicin, the cell cycle profiles for both *B-Myb* overexpressing cells and controls were identical in terms of the percentage of cells in G1 and G2/M phase ([Figure 5](#F5){ref-type="fig"}). However, at low and intermediate concentrations (10-35 nM) of doxorubicin there was a significant difference in the number of cells in G1 or G2/M with a larger percentage of *B-Myb* overexpressing cells in G1 versus controls, and a lower percentage of *B-Myb* overexpressing cells in G2/M ([Figure 5A and 5B](#F5){ref-type="fig"}, respectively); very similar results were obtained with etoposide treatment ([Supplementary Figure 3](#SD1){ref-type="supplementary-material"}). At high doses of doxorubicin or etoposide, regardless of *B-Myb* expression, the majority of cells arrested in G2/M.

DISCUSSION {#S8}
==========

Clinically defined as ER-, PR-, and HER2 not amplified, the basal-like subtype of breast cancer portends a poor prognosis. Basal-like breast cancer has an inherently high proliferation rate, which by microarray is identified by high expression of the "proliferation signature" genes; this signature has been identified in many publications, in many tumor types, and is highly enriched for cell cycle regulated genes ([@R42]). Here, we find that *B-Myb*, a gene highly expressed within the proliferation cluster, plays an important role in regulating cell cycle progression, which likely has effects on patient prognosis and response to chemotherapy.

We showed that *B-Myb* high expression was significantly associated with the poor outcome, basal-like breast cancer subtype and that *B-Myb* gene expression levels alone predicted poor outcomes in the absence of therapy (i.e. prognosis, [Figure 2](#F2){ref-type="fig"}) and are correlated with achieving a pCR (i.e. prediction, [Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Stratification of *B-Myb* expression, even within the luminal A, B, and HER2+/ER− subtypes, or ER+ tumors, was significantly associated with survival. Stratification of *B-Myb* expression *within* basal-like tumors did not predict outcomes, nor was outcome predicted in the ER− subset of the [@R41] dataset (which includes basal-like tumors); however, these are inherently poor outcome tumors that significantly trend towards high *B-Myb* expression ([Figure 1](#F1){ref-type="fig"}).

The *B-Myb* chromosomal locus, 20q13, is found amplified in a variety of cancers, including breast ([@R4]), and this amplification is linked to poor prognosis ([@R1]). Gene copy number analysis across breast tumor subtypes suggested that the genomic amplification of *B-Myb* was not enriched in the basal-like subtype, but instead was enriched in the luminal B subtype ([@R1]). Therefore, within luminal tumors, *B-Myb* amplification and expression is an event that appears to be selected for and portends a poor prognosis ([Figures 2B, C](#F2){ref-type="fig"}). In basal-like tumors the high expression of *B-Myb* may be due to other regulatory mechanisms, possibly by virtue of their inherently high proliferation rates, by amplification of transcription factor(s) targeting *B-Myb*, or by selectively enhanced promoter activity. This dual behavior of basal-like tumors, a subtype typical of chemo-responsiveness but with poor patient outcomes, has been described before and termed the "basal-like tumor paradox" ([@R3]), and the data presented here suggest that B-Myb may be a key regulator of this complex phenotype.

Recently, [@R30], linked the nonsynonymous *B-Myb* germline variant (S427G, rs2070235) to a decrease in overall cancer risk when combining neuroblastomas, chronic myelogenous leukemia, and colon cancers into a single dataset and comparing this grouping of cases to non-cancer bearing controls. While both studies are technically accurate (i.e. similar allele frequencies in the control populations; CBCS: homozygous major allele 72.6%, heterozygous 24%, homozygous minor allele 3.4%; [@R30]: 72.1%, 27.3%, and 0.4%, respectively), the association of *B-Myb* rs2070235 genotype and basal-like breast cancer susceptibility differs from the previous report and has not been described before. Here, in a population based case-control study, we found that the rs2070235 minor allele was associated with increased risk of basal-like breast cancer but not other subtypes in the CBCS ([Table 1](#T1){ref-type="table"}). The discrepancy between the Schwab data and what is reported here may be due to differences between breast cancer and the cancers examined in the Schwab paper. Even amongst breast cancers there is significant heterogeneity across the subtypes in terms of the etiologic role of the *B-Myb* allele, and an analysis of breast cancer without subdivision would have missed the association of rs2070235 with the basal-like breast cancer subtype.

Presently, the function of the S427G variant is unknown. Our *in vitro* studies in breast epithelial cell lines showed neither a phenotypic difference between the overexpression of *B-Myb* or its variant on chemosensitivity relative to each other, nor did we observe a difference in their baseline gene expression patterns. It is temping to speculate that rs2070235 has functional consequences and somehow contributes to the etiology of basal-like tumors. The *B-Myb* variant was found to be nearly ten-fold more frequent in African-Americans (7%) versus non-African-Americans (0.8%) in the CBCS. This is relevant in light of recent data showing that premenopausal African-Americans are approximately twice as likely to develop basal-like tumors compared with premenopausal Caucasians ([@R3]; [@R19]). Of note, [@R30] demonstrated that the B-Myb S427G protein was more stable than the wild-type protein. This increased stability may correspond to elevated B-Myb protein levels, possibly increasing transcriptional activity of G2/M cell cycle genes and leading to higher inherent proliferation rates. This alteration of cell cycle control may contribute to B-Myb's influence on poor outcome breast cancers. Additional assays are required to more fully investigate the role of rs2070235 and other variants in *B-Myb* that may also lie in linkage disequilibrium with the G allele. This is an important area of investigation, since it is possible that one or more variants in *B-Myb* could contribute to the higher frequency of basal-like breast cancer among African-American breast cancer patients and may contribute to the pathophysiology of basal-like breast cancer.

Since chemotherapy is currently the only option for basal-like patients, we explored if increased *B-Myb* expression had any effect on chemosensitivity *in vitro*. We observed a statistically significant increase in sensitivity to two TOP2A inhibitors, doxorubicin and etoposide, in the HME-CC and ME16C cells overexpressing *B-Myb* or its variant, but this phenotype was not observed in the basal-like tumor derived cell lines ([Figure 3](#F3){ref-type="fig"}). Also, there was no significant difference in chemosensitivity to the other tested drugs in any of the cell lines, which included camptothecin, a DNA topoisomerase I (TOP1) inhibitor. TOP2A, a nuclear enzyme that relaxes both negative and positive DNA supercoils by creating double-stranded DNA breaks, is of particular importance for proper DNA duplication during S-phase of the cell cycle ([@R31]). TOP2A inhibitors cause the enzyme to become trapped on double-strand DNA breakpoints, thereby causing G2 cell cycle checkpoint arrest. Since *B-Myb* is a G2/M regulating gene, increased *B-Myb* expression may be promoting the TOP2A-inhibitor treated cells through the G2 checkpoint via induction of downstream B-Myb target genes. By facilitating cells through G2, with less regard for DNA damage, the *B-Myb* overexpressing cells may attempt to cycle again, eventually leading to the increased sensitivity to TOP2A phenotype observed. TOP2A itself was on the B-Myb induced gene list ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}) and thus more of the target of doxorubicin and etoposide was present, adding to the observed sensitivity phenotype in *B-Myb* overexpressing cells.

In support of this hypothesis, the gene list identified by microarray analysis as being highly expressed in doxorubicin-treated, *B-Myb* overexpressing cells ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}) was significantly enriched in genes required for G2/M progression. For example, this list included the newly described B-Myb interacting protein LIN-9, a protein required along with B-Myb for the transcription of G2/M genes ([@R24]). In addition, our B-Myb target gene list contained many previously identified B-Myb targets including *CDC2*, *Cyclin B1*, and *BIRC5* ([@R44]; [@R24]). This gene list represents putative mammary B-Myb target genes and again suggests that B-Myb has its greatest effect on G2/M genes. In agreement with the gene list enrichment results, when *B-Myb* overexpressing cells were treated with low doses of doxorubicin or etoposide, more cells accumulated in G1 versus controls, suggesting that the control cell line was appropriately inhibiting cell cycle progression at G2, whereas *B-Myb* overexpressing lines were bypassing this checkpoint ([Figure 5](#F5){ref-type="fig"}).

The results of this study enhance our understanding of the role of B-Myb in breast cancer by identifying new B-Myb target genes, by showing that this gene is highly expressed in basal-like breast cancers, and by showing it is of prognostic value for survival and predictive value for pathological complete response. Also, we have described a significant correlation between a *B-Myb* variant and an increased risk of basal-like breast cancer. These findings point to B-Myb as a biomarker that is of potential clinical importance for determining disease risk and for guiding treatment. In addition to its role in basal-like cancers, *B-Myb* may also be of great importance in luminal tumors, a breast cancer subtype with relatively good prognosis, since *B-Myb* expression was capable of stratifying the poor from the good actors within this group, and it is within this group where *B-Myb* is occasionally amplified on the DNA level. The link between *B-Myb* high expression and increased chemotherapy sensitivity *in vitro* is mirrored by similar findings *in vivo* where we and others have shown that basal-like tumors are, on average, the most sensitive to multi-agent chemotherapy regimens that contain an anthracycline ([@R28]; [@R2]). It is unlikely that *B-Myb* expression alone is responsible for the chemotherapy sensitivity of basal-like tumors, but when coupled with the loss of TP53 function, which is known to occur in basal-like tumors ([@R32]), and the loss of RB function ([@R6]; [@R7]), multiple important checkpoints are deficient in basal-like tumors and it is this lack of control that may ultimately prove to be their Achilles' heel.

Materials and Methods {#S9}
=====================

Cell Lines {#S10}
----------

*hTERT*-immortalized, human mammary epithelial cell lines (HME-CC, ME16C), and basal-like breast cancer-derived lines (SUM102, SUM149) were cultured as described ([@R37]; [@R9]). Full-length, human *B-Myb* cDNA (GenBank NM_002466) was cloned into the pBabe.puro.GWrfA (Gateway Reading Frame A) vector using Gateway® Cloning Technology (Invitrogen, Carlsbad, CA, USA). Retrovirus was produced in Phoenix 293T cells by transfecting with ten micrograms of vector using Lipofectamine 2000 (Invitrogen), as per manufacturer's instructions. Media was changed 24 hours post-transfection and supernatants collected 12 hours later. Seventy-five micrograms of polybrene were added to the collected supernatants and applied to the mammary cell lines. Stable populations were selected by culturing in 1 ug/mL puromycin for HME-CC and ME16C, or 0.5 ug/mL puromycin for SUM102 and SUM149.

*B-Myb* variant (S427G) was created in the pBabe.puro.B-Myb expression vector using QuikChange® XL Site-Directed Mutagenesis Kit (Stratagene, Los Angeles, CA, USA).

Western Blot Analysis {#S11}
---------------------

Cells were grown in 10 cm tissue culture-treated dishes until 80 percent confluence, followed by harvest, protein isolation and quantification as previously described ([@R37]). Membranes were probed for B-Myb (sc-725; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), and β-actin (AC-15; Abcam, Cambridge, MA, USA), followed by anti-rabbit or anti-mouse IgG horseradish peroxidase-linked whole antibody (Amersham Biosciences) and detected using SuperSignal West Pico Chemiluminescent Substrate (Pierce, Rockford, IL, USA).

Cell Cycle Analysis {#S12}
-------------------

Cells were treated with a range of doxorubicin (0-70 nM) or etoposide (0-2 nM) doses and DNA content was analyzed using a modified propidium iodide staining assay. Briefly, one million cells were collected by trypsinization, washed in 1x PBS, and fixed in 70% ethanol at 4C overnight. Cells were washed with PBS/0.2% BSA and resuspended in 500 microliters of PBS/0.2% BSA and 100 micrograms RNaseA. Propidium iodide was added to a final volume of 50 micrograms, and cells incubated at 37C for 30 minutes. DNA content analysis was performed using a FACScan flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). To determine fractions of cells in G1 and G2/M phases, histograms of DNA content were analyzed using Summit v4.3 software (Dako, Carpinteria, CA, USA) gating around 2N and 4N DNA content. Analyses were done on three separate days and mean values were calculated.

Cytotoxicity Assay {#S13}
------------------

Cell line sensitivities to drugs were assessed using a modified mitochondrial dye conversion assay (Cell-Titer 96, Promega \#G4100, Madison, WI, USA) as described ([@R37]; [@R9]). Chemotherapeutics (carboplatin, doxorubicin, 5-fluorouracil, paclitaxel, etoposide, camptothecin) were purchased from Sigma (St. Louis, MO, USA). The 72-hour inhibitory concentration that caused a 50% reduction in MTT dye conversion (IC50) was determined using nonlinear regression (SAS Statistical Software, Cary, NC, USA) ([@R40]). Differences in the IC50 estimates were tested by a traditional ANOVA test of nested models was performed using the R system for statistical computing (R Development Core Team, 2006 <http://www.R-project.org>).

Microarray Analysis {#S14}
-------------------

Five replicates each of HME-CC *B-Myb*-overexpressing and vector control cell lines were treated with the 72-hour IC50 dose of doxorubicin. Poly-A(+) RNA was collected (Micro-FastTrack2.0 mRNA Isolation Kit, Invitrogen) from treated control cells and *B-Myb* overexpressing lines, reverse transcribed and labeled using the Agilent Low RNA Input Linear Amplification Kit (Agilent Technologies, Santa Clara, CA, USA), and hybridized to Agilent Human 44K Custom Oligo microarrays as described ([@R12]). An untreated HME-CC cell line reference was co-hybridized to all arrays (e.g. untreated HME-CC vs. doxorubicin-treated empty vector HME-CC). Microarrays were scanned on an Axon Genepix 4000B microarray scanner and analyzed using GenePix Pro 5.1 software (Molecular Devices, Sunnyvale, CA, USA). Data was normalized using Lowess normalization on the Cy3 and Cy5 channels. Microarray data is available at the UNC Microarray Database \[<http://genome.unc.edu>\] and at the Gene Expression Omnibus (GSE11429).

Microarray Statistical Analyses {#S15}
-------------------------------

Supervised microarray analysis was performed by selecting genes with an absolute signal intensity of at least 30 units in both dye channels and data present in at least 70% of experimental samples. A two-class, unpaired Significance Analysis of Microarrays (SAM) was performed to identify significant genes associated with *B-Myb* expression with a false discovery rate (FDR) of less than 3% ([@R38]).

The Netherlands Cancer Institute breast cancer dataset (NKI-295, n=295) was used for analysis of *B-Myb* expression across breast cancer subtypes ([@R39]); however, only locally-treated tumors (no chemotherapy) were used in survival analyses (n=165). Association of *B-myb* expression states (rank ordered and split in halves: low/high) relative to survival was tested using the Cox-Mantel log-rank test and results visualized using Kaplan-Meier survival plots (WinSTAT v.2007.1). Testing the association of *B-myb* expression versus subtypes was performed using ANOVA. Three other published datasets were analyzed, as above, for survival ([@R17]; [@R41]) or pathological response ([@R8]) by chi-square using the R system for statistical computing.

*B-Myb* Genotyping (CBCS) {#S16}
-------------------------

The Carolina Breast Cancer Study (CBCS) is a population-based, case-control study of breast cancer conducted in 24 counties of central and eastern North Carolina between 1993 and 2001 ([@R22]; [@R18]). *B-Myb* genotyping (rs2070235) was conducted using DNA extracted from peripheral blood lymphocytes for 1256 cases with subtype information (500 African-American, 756 Caucasian) and 1814 controls (679 African-American, 1135 Caucasian). For complete details see Supplementary Materials.

Supplementary Material {#SM}
======================

We thank Drs. Melissa A. Troester and William K. Kaufmann for comments and discussion. This work was supported by funds from the NCI Breast SPORE program (P50-CA58223-09A1), by RO1-CA-101227-01, by the Breast Cancer Research Foundation and the V Foundation for Cancer Research.

![*B-Myb* expression across breast cancer subtypes\
The NKI breast tumor microarray dataset (n=295) was classified into the five intrinsic subtypes and box plots used to visualize *B-Myb* expression according to breast cancer subtypes. Statistical significance was calculated by ANOVA.](nihms-76747-f0001){#F1}

![High expression of *B-Myb* correlates with poor outcome\
Kaplan-Meier survival analyses based on *B-Myb* expression values rank ordered into halves (low/high). (A-D) Overall survival (OS) of locally treated NKI tumor samples: (A) All subtypes combined (n=165), (B) Luminal A (n=72), (C) Luminal B (n=26), (D) HER2+/ER− (n=21). (E) RFS, [@R41] (n=286), a locally treated, lymph-node-negative tumor microarray dataset. (F) [@R17] breast tumor microarray dataset (n=234).](nihms-76747-f0002){#F2}

![Drug sensitivities in *B-Myb* overexpressing cell lines\
IC50 doses (72h) of chemotherapy on cell lines stably expressing vector control, *B-Myb*, or *B-Myb* S427G variant. Each MTT experiment was performed in triplicate and error bars represent 95% confidence intervals (\*p\<0.001 relative to vector control). (A) *hTERT*-immortalized HMEC line HME-CC. (B) *hTERT*-immortalized HMEC line ME16C. (C) Basal-like tumor derived cell line SUM102 and (D) SUM149.](nihms-76747-f0003){#F3}

![Enrichment of G2/M phase genes in doxorubicin-treated *B-Myb* overexpressing HME-CC cells\
Significance Analysis of Microarray was used to identify 217 significant genes whose high expression was present in *B-Myb* overexpressing cells. These genes were then assigned to a specific phase of the cell cycle by comparing them to [@R43], which identified 101/217 genes as being specifically induced during the cell cycle. The graph shows to which phase of the cell cycle these 101 genes mapped.](nihms-76747-f0004){#F4}

![Cell cycle profile of HME-CC cells stably expressing *B-Myb* and treated with doxorubicin\
Cell cultures were treated with a range of doses of doxorubicin for 48 hours followed by propidium iodide DNA content analysis. Percentage of cells in (A) G1 phase and (B) G2/M were calculated by gating based on DNA content. Error bars indicate standard deviations between three independent experiments.](nihms-76747-f0005){#F5}

###### *B-Myb* variant genotype (G/G) increases the risk of basal-like breast cancer

Odds ratios for the *B-Myb* genotype and basal-like, luminal A, and all breast cancer cases. Patient samples were genotyped for the *B-Myb* polymorphism at codon 427, rs2070235 (A: wild-type; G: variant).

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  B-Myb\           Controls\   Basal-like\   OR (95% Cl)[a](#TFN1){ref-type="table-fn"}   Luminal A\   OR (95% Cl)[a](#TFN1){ref-type="table-fn"}   All cases\   OR (95% Cl)[a](#TFN1){ref-type="table-fn"}
  Genotype         (N=1814)    cases\                                                     cases\                                                    (N=1256)     
                               (N=206)                                                    (N=698)                                                                
  ---------------- ----------- ------------- -------------------------------------------- ------------ -------------------------------------------- ------------ --------------------------------------------
  **A/A**          1319        131           Referent                                     531          Referent                                     912          Referent

  **A/G**          436         60            1.2 (0.8-1.7)                                149          0.8 (0.7-1.1)                                301          1.O (0.8-1.2)

  **G/G**          59          15            **2.0 (1.1-3.8)**                            18           0.8 (0.5-1.4)                                43           1.O (0.6-1.5)

  **Trend test**                             **p=0.047**                                               p=0.14                                                    p=0.71
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Adjusted for offsets, age, and race

###### Top 15 significant gene ontology categories determined by EASE analysis for *B-Myb* associated genes

Significant genes, as determined by SAM, for doxorubicin-treated *B-Myb* overexpressing HME-CC cells versus doxorubicin-treated controls were input to EASE and analyzed for enriched gene ontology categories.

  Doxorubicin-induced genes:                                       
  -------------------------------------- ---- ----- ------ ------- -----------
  Mitotic cell cycle                     58   138   352    13248   2.59E-51
  Cell cycle                             65   138   745    13248   8.60E-41
  M phase                                37   138   174    13248   1.22E-34
  Nuclear division                       35   138   167    13248   2.84E-32
  Mitosis                                32   138   131    13248   2.31 E-31
  M phase of mitotic cell cycle          32   138   133    13248   3.87E-31
  Cell proliferation                     65   138   1116   13248   4.33E-30
  DNA replication and chromosome cycle   29   138   199    13248   2.21 E-21
  DNA metabolism                         36   138   579    13248   4.60E-15
  DNA replication                        20   138   156    13248   1.22E-12
  S phase of mitotic cell cycle          20   138   158    13248   1.54E-12
  Spindle                                17   135   97     12954   1.66E-12
  Regulation of cell cycle               28   138   406    13248   4.68E-12
  Cytokinesis                            16   138   112    13248   3.14E-10
  Cell growth and/or maintenance         81   138   3996   13248   3.44E-09
